$MRK Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma (Merck &amp; Co Inc)
(More at https://t.co/Mnk5zjE4mz)